Epigenetic modification of hepatitis B virus infection and related hepatocellular carcinoma.

Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101531386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2150-5608 (Electronic) Linking ISSN: 21505594 NLM ISO Abbreviation: Virulence Subsets: MEDLINE

Publication: 2015- : Philadelphia, PA : Taylor & Francis
Original Publication: Austin, Tex. : Landes Bioscience

Carcinoma, Hepatocellular*/genetics ; Carcinoma, Hepatocellular*/pathology ; Carcinoma, Hepatocellular*/virology ; Epigenesis, Genetic* ; Hepatitis B virus*/genetics ; Hepatitis B virus*/pathogenicity ; Hepatitis B, Chronic*/complications ; Hepatitis B, Chronic*/genetics ; Hepatitis B, Chronic*/pathology ; Hepatitis B, Chronic*/virology ; Liver Neoplasms*/genetics ; Liver Neoplasms*/pathology ; Liver Neoplasms*/virology; Humans ; DNA Methylation ; Host-Pathogen Interactions/genetics

Hepatitis B virus (HBV) infection poses a challenge to global public health. Persistent liver infection with HBV is associated with an increased risk of developing severe liver disease. The complex interaction between the virus and the host is the reason for the persistent presence of HBV and the risk of tumor development. Chronic liver inflammation, integration of viral genome with host genome, expression of HBx protein, and viral genotype are all key participants in the pathogenesis of hepatocellular carcinoma (HCC). Epigenetic regulation in HBV-associated HCC involves complex interactions of molecular mechanisms that control gene expression and function without altering the underlying DNA sequence. These epigenetic modifications can significantly affect the onset and progression of HCC. This review summarizes recent research on the epigenetic regulation of HBV persistent infection and HBV-HCC development, including DNA methylation, histone modification, RNA modification, non-coding RNA, etc. Enhanced knowledge of these mechanisms will offer fresh perspectives and potential targets for intervention tactics in HBV-HCC.

Oncotarget. 2015 Oct 20;6(32):33791-804. (PMID: 26393879)
World J Gastroenterol. 2014 Sep 14;20(34):12039-44. (PMID: 25232241)
Aging (Albany NY). 2023 Aug 1;15(15):7533-7550. (PMID: 37531206)
Ann Hepatol. 2022 May-Jun;27(3):100688. (PMID: 35196550)
Cell. 2007 Feb 23;128(4):693-705. (PMID: 17320507)
Br J Cancer. 2015 Jul 14;113(2):252-8. (PMID: 26125451)
PLoS Pathog. 2013 Sep;9(9):e1003613. (PMID: 24068929)
J Hepatocell Carcinoma. 2021 May 28;8:493-505. (PMID: 34095004)
Med Oncol. 2009 Dec;26(4):445-51. (PMID: 19082926)
Viruses. 2022 Feb 21;14(2):. (PMID: 35216027)
Int J Oncol. 2016 Aug;49(2):589-602. (PMID: 27221337)
World J Gastroenterol. 2017 Jul 7;23(25):4569-4578. (PMID: 28740345)
Epigenetics. 2016 Jun 2;11(6):464-74. (PMID: 27248055)
Int J Mol Sci. 2015 Sep 18;16(9):22662-75. (PMID: 26393582)
Sci Adv. 2021 Jun 16;7(25):. (PMID: 34134995)
World J Gastroenterol. 2011 Oct 14;17(38):4258-70. (PMID: 22090781)
Hepatol Commun. 2019 Oct 10;4(1):8-20. (PMID: 31909352)
Cancer Lett. 2014 Jan 28;342(2):223-30. (PMID: 22306342)
Hepatology. 2016 Jan;63(1):261-83. (PMID: 26566064)
RNA Biol. 2017 Oct 3;14(10):1389-1398. (PMID: 28267418)
Microbiol Spectr. 2023 Aug 25;:e0164123. (PMID: 37623314)
Clin Cancer Res. 2007 Apr 15;13(8):2378-84. (PMID: 17438096)
Cancer Manag Res. 2020 Feb 11;12:1007-1015. (PMID: 32104082)
Biosci Rep. 2019 Jul 5;39(7):. (PMID: 31164410)
Front Microbiol. 2022 Jan 24;12:795388. (PMID: 35140694)
Adv Sci (Weinh). 2022 May;9(16):e2103135. (PMID: 35398991)
Sci Rep. 2021 Jan 13;11(1):1136. (PMID: 33441885)
Cancer Med. 2020 Mar;9(5):1877-1889. (PMID: 31943856)
Sci Rep. 2018 Jul 11;8(1):10461. (PMID: 29992971)
Cell. 1986 Nov 7;47(3):451-60. (PMID: 3768961)
J Hepatol. 2016 Aug;65(2):280-8. (PMID: 26952006)
PLoS Pathog. 2023 Dec 4;19(12):e1011808. (PMID: 38048324)
Oncogene. 2021 Jan;40(1):28-45. (PMID: 33051595)
Front Oncol. 2021 Oct 26;11:747022. (PMID: 34765551)
Virol Sin. 2015 Apr;30(2):85-91. (PMID: 25862579)
J Exp Clin Cancer Res. 2023 Oct 16;42(1):267. (PMID: 37840133)
Hepatology. 2006 Feb;43(2 Suppl 1):S173-81. (PMID: 16447285)
J Virol. 1994 Aug;68(8):5232-8. (PMID: 8035519)
Front Immunol. 2016 Aug 31;7:335. (PMID: 27630638)
Mol Diagn Ther. 2018 Apr;22(2):157-168. (PMID: 29335927)
Nucleic Acids Res. 2014 Jun;42(10):6578-90. (PMID: 24705650)
Oncotarget. 2017 Jan 3;8(1):1132-1140. (PMID: 27902472)
Exp Mol Med. 2017 Feb 10;49(2):e293. (PMID: 28186085)
Int J Clin Exp Pathol. 2017 Oct 01;10(10):10325-10333. (PMID: 31966367)
J Exp Clin Cancer Res. 2017 Oct 19;36(1):148. (PMID: 29052520)
Hepatology. 2017 Dec;66(6):2066-2077. (PMID: 28833361)
Cancer Immunol Immunother. 2019 Mar;68(3):379-393. (PMID: 30547218)
Nat Genet. 2012 May 06;44(6):694-8. (PMID: 22561517)
Nat Genet. 2011 Aug 07;43(9):828-9. (PMID: 21822264)
Cell Signal. 2013 Feb;25(2):439-46. (PMID: 23124077)
J Exp Clin Cancer Res. 2016 Oct 19;35(1):164. (PMID: 27756432)
J Cell Commun Signal. 2022 Jun;16(2):179-190. (PMID: 34535871)
Cancer Res. 2019 Mar 1;79(5):941-953. (PMID: 30530815)
Cancer Lett. 2009 Jul 18;280(1):78-85. (PMID: 19321255)
J Immunother Cancer. 2019 Nov 14;7(1):300. (PMID: 31727135)
Oncol Lett. 2017 Aug;14(2):2025-2032. (PMID: 28789433)
J Cell Physiol. 2019 Aug;234(8):12369-12384. (PMID: 30605237)
Genes Cancer. 2011 Jun;2(6):607-17. (PMID: 21941617)
J Virol. 2021 Jun 10;95(13):e0009721. (PMID: 33883220)
Biomed Res Int. 2018 May 15;2018:4793971. (PMID: 29862272)
Cell Death Dis. 2019 Apr 15;10(5):333. (PMID: 30988277)
Clin Epigenetics. 2020 Sep 7;12(1):135. (PMID: 32894195)
Front Pharmacol. 2021 Jun 24;12:707930. (PMID: 34248650)
BMC Cancer. 2021 Jun 10;21(1):686. (PMID: 34112124)
Biochim Biophys Acta. 2007 Sep;1772(9):1075-84. (PMID: 17669635)
Cancer Cell Int. 2023 Sep 9;23(1):199. (PMID: 37689710)
Per Med. 2021 Mar;18(2):97-106. (PMID: 33565325)
IUBMB Life. 2019 Sep;71(9):1336-1346. (PMID: 31018043)
Antiviral Res. 2010 Nov;88(2):169-75. (PMID: 20728471)
Cell Mol Immunol. 2015 May;12(3):292-302. (PMID: 25308752)
Br J Cancer. 2020 May;122(10):1428-1440. (PMID: 32231294)
J Gastroenterol. 2016 May;51(5):473-86. (PMID: 26553052)
Lancet Gastroenterol Hepatol. 2022 Sep;7(9):796-829. (PMID: 35738290)
Theranostics. 2019 Jul 9;9(18):5227-5245. (PMID: 31410212)
Cancer Metastasis Rev. 2023 Sep;42(3):629-652. (PMID: 36729264)
IUBMB Life. 2021 Feb;73(2):408-417. (PMID: 33372396)
Oncol Rep. 2020 Sep;44(3):973-986. (PMID: 32705223)
Cold Spring Harb Perspect Med. 2015 Nov 09;5(12):. (PMID: 26552701)
Clin Epigenetics. 2023 Mar 17;15(1):43. (PMID: 36932439)
Aliment Pharmacol Ther. 2023 Nov;58(10):1086-1098. (PMID: 37644711)
Cancer Cell Int. 2022 May 16;22(1):192. (PMID: 35578240)
PLoS Pathog. 2017 Feb 24;13(2):e1006239. (PMID: 28235042)
Cells. 2022 Nov 02;11(21):. (PMID: 36359865)
Nat Commun. 2018 Mar 28;9(1):1241. (PMID: 29593314)
Gut. 2022 Mar;71(3):616-626. (PMID: 33563643)
J Hepatol. 2022 Jun;76(6):1249-1262. (PMID: 35589248)
iScience. 2021 Jan 04;24(1):101969. (PMID: 33458618)
Clin Transl Med. 2023 Feb;13(2):e1198. (PMID: 36792369)
Virus Res. 2009 Jan;139(1):14-21. (PMID: 18948152)
Cell Death Dis. 2022 Jul 23;13(7):642. (PMID: 35871161)
Front Endocrinol (Lausanne). 2018 Aug 03;9:402. (PMID: 30123182)
Cell Microbiol. 2017 May;19(5):. (PMID: 27886437)
Hepatology. 2021 Feb;73(2):533-547. (PMID: 32394474)
Sci Rep. 2015 Nov 16;5:16489. (PMID: 26568165)
Int J Cancer. 2014 Aug 1;135(3):635-46. (PMID: 24374650)
Cell Death Dis. 2019 Oct 14;10(10):783. (PMID: 31611549)
J Cell Physiol. 2018 Aug;233(8):5574-5588. (PMID: 29521426)
Proc Natl Acad Sci U S A. 2021 Jan 19;118(3):. (PMID: 33397803)
Nat Genet. 2012 Oct;44(10):1117-21. (PMID: 22922871)
Viruses. 2024 Apr 15;16(4):. (PMID: 38675950)
Oncotarget. 2015 May 20;6(14):12723-39. (PMID: 25909289)
Gastroenterology. 2007 Apr;132(4):1476-94. (PMID: 17408664)
Emerg Microbes Infect. 2021 Dec;10(1):2264-2275. (PMID: 34767497)
PLoS One. 2017 Jul 24;12(7):e0181858. (PMID: 28742130)
Int J Mol Sci. 2024 Jan 12;25(2):. (PMID: 38256049)
Ann Hepatol. 2019 Nov - Dec;18(6):869-878. (PMID: 31477445)
Theranostics. 2021 Jan 1;11(5):2318-2333. (PMID: 33500727)
J Virol. 2021 Jan 13;95(3):. (PMID: 33148795)
Biomed Pharmacother. 2019 Apr;112:108613. (PMID: 30784918)
Int J Cancer. 2019 May 15;144(10):2489-2500. (PMID: 30125344)
Int J Biol Sci. 2022 Aug 1;18(13):5001-5018. (PMID: 35982895)
Cancer Lett. 2023 Apr 10;559:216122. (PMID: 36898427)
Front Cell Infect Microbiol. 2022 Jun 02;12:790964. (PMID: 35719345)
Cancer Res. 2014 Mar 1;74(5):1452-62. (PMID: 24390737)
Cancers (Basel). 2022 Jan 29;14(3):. (PMID: 35158962)
J Hepatol. 2009 Sep;51(3):581-92. (PMID: 19616338)
Cancer Lett. 2003 Feb 20;190(2):213-9. (PMID: 12565176)
World J Gastroenterol. 2012 Oct 14;18(38):5442-53. (PMID: 23082062)
EMBO J. 2020 Jun 17;39(12):e103181. (PMID: 32368828)
JAMA. 2006 Jan 4;295(1):65-73. (PMID: 16391218)
Hepatology. 2018 Oct;68(4):1412-1428. (PMID: 29774579)
Hepatology. 2017 Oct;66(4):1296-1313. (PMID: 28762522)
J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:144-52. (PMID: 21199526)
Cancer Manag Res. 2019 Oct 16;11:8947-8963. (PMID: 31802937)
J Hepatol. 2018 Jul;69(1):182-236. (PMID: 29628281)
Nat Genet. 2012 May 27;44(7):765-9. (PMID: 22634754)
J Biol Chem. 2011 Aug 26;286(34):29540-7. (PMID: 21737444)
Nat Rev Immunol. 2003 Nov;3(11):900-11. (PMID: 14668806)
J Exp Med. 2000 Apr 17;191(8):1269-80. (PMID: 10770795)
Bioengineered. 2022 Mar;13(3):7829-7846. (PMID: 35291921)
Medicina (Kaunas). 2019 Aug 23;55(9):. (PMID: 31450841)
BMC Genomics. 2017 Feb 17;18(1):184. (PMID: 28212627)
J Virol. 2004 Dec;78(23):12725-34. (PMID: 15542625)
J Cell Mol Med. 2020 Jan;24(2):1848-1865. (PMID: 31880390)
J Hepatol. 2015 Nov;63(5):1093-102. (PMID: 26143443)
Hepatology. 2002 Sep;36(3):692-701. (PMID: 12198663)
Cancers (Basel). 2023 Mar 10;15(6):. (PMID: 36980601)
Nature. 2004 Sep 16;431(7006):350-5. (PMID: 15372042)
Proc Natl Acad Sci U S A. 2018 Aug 28;115(35):8829-8834. (PMID: 30104368)
Nature. 2017 Dec 14;552(7684):273-277. (PMID: 29211711)
Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19975-9. (PMID: 19906987)
Immunity. 2016 May 17;44(5):989-1004. (PMID: 27192565)
Avicenna J Med Biotechnol. 2010 Oct;2(4):161-79. (PMID: 23407304)
Int J Mol Sci. 2021 Sep 12;22(18):. (PMID: 34576022)
Immunity. 2015 Jan 20;42(1):123-32. (PMID: 25557055)
Nat Commun. 2021 Mar 19;12(1):1786. (PMID: 33741974)
Nat Genet. 2012 May 27;44(7):760-4. (PMID: 22634756)
Hepatol Int. 2023 Jun;17(3):735-744. (PMID: 36738397)
J Exp Clin Cancer Res. 2022 Mar 3;41(1):83. (PMID: 35241126)
Curr Pharm Des. 2014;20(11):1715-25. (PMID: 23888939)
Mol Ther Nucleic Acids. 2022 May 20;29:47-63. (PMID: 35795482)
Emerg Microbes Infect. 2022 Dec;11(1):616-628. (PMID: 35109781)
J Virol. 2022 Feb 23;96(4):e0165521. (PMID: 34851655)
PLoS Pathog. 2021 Jan 25;17(1):e1009230. (PMID: 33493210)
Sci Rep. 2015 May 22;5:10478. (PMID: 26000761)
Cancer Cell. 2012 Apr 17;21(4):504-16. (PMID: 22516259)
Science. 2022 May 27;376(6596):968-973. (PMID: 35511947)
J Immunol Res. 2021 Jul 01;2021:9965099. (PMID: 34307695)
Science. 1993 Apr 16;260(5106):309-10. (PMID: 8469984)
J Exp Med. 2006 Jun 12;203(6):1391-7. (PMID: 16717119)
Front Med (Lausanne). 2022 Mar 02;9:821710. (PMID: 35308519)
Epigenetics. 2016 Oct 2;11(10):709-720. (PMID: 27646854)
Cell. 2007 Nov 16;131(4):633-6. (PMID: 18022353)
Cancer Cell Int. 2020 Nov 10;20(1):547. (PMID: 33292241)
Cell Death Dis. 2021 Jul 23;12(8):731. (PMID: 34301921)
Hepatology. 2011 Mar;53(3):1020-2. (PMID: 21374666)
Mol Cancer Res. 2024 Sep 4;22(9):891-901. (PMID: 38787319)
J Cell Mol Med. 2018 Jun;22(6):3192-3201. (PMID: 29602251)
Int J Mol Sci. 2022 Jul 29;23(15):. (PMID: 35955552)
Theranostics. 2020 May 15;10(14):6261-6277. (PMID: 32483452)
Front Microbiol. 2018 Jul 18;9:1611. (PMID: 30072974)
Plant Physiol. 2020 Jan;182(1):15-26. (PMID: 31685643)
Heliyon. 2023 Nov 23;9(12):e22595. (PMID: 38125436)
Gastroenterology. 2012 Sep;143(3):811-820.e15. (PMID: 22641068)
Sci Rep. 2017 Jan 05;7:40089. (PMID: 28053323)
Am J Transl Res. 2019 Sep 15;11(9):6084-6092. (PMID: 31632576)
Cell. 2017 Jun 15;169(7):1187-1200. (PMID: 28622506)
Front Oncol. 2020 Nov 27;10:581007. (PMID: 33330058)
Sci Transl Med. 2017 Sep 27;9(409):. (PMID: 28954926)
Front Cell Infect Microbiol. 2023 Mar 15;13:1128807. (PMID: 37009498)
World J Gastroenterol. 2016 Aug 7;22(29):6663-72. (PMID: 27547009)
Hum Vaccin Immunother. 2023 Dec 31;19(1):2161254. (PMID: 36683193)
Antiviral Res. 2015 Sep;121:82-93. (PMID: 26129969)
Antiviral Res. 2020 Oct;182:104925. (PMID: 32866519)
Mol Cancer. 2020 Apr 27;19(1):79. (PMID: 32340605)
Heliyon. 2024 Feb 29;10(5):e26767. (PMID: 38463829)
J Virol. 2010 May;84(9):4321-9. (PMID: 20147412)
Cancer Sci. 2019 May;110(5):1633-1643. (PMID: 30891870)
Heliyon. 2022 Jul 05;8(7):e09881. (PMID: 35832344)
Nature. 2015 Jan 15;517(7534):321-6. (PMID: 25592537)
World J Gastroenterol. 2017 May 14;23(18):3252-3261. (PMID: 28566884)
Gastroenterology. 2006 Mar;130(3):823-37. (PMID: 16530522)
Int J Clin Exp Pathol. 2019 Nov 01;12(11):4041-4056. (PMID: 31933800)
Int J Cancer. 2018 Dec 15;143(12):3120-3130. (PMID: 29752719)
Cell Metab. 2014 Oct 7;20(4):626-38. (PMID: 25295787)
Curr Oncol. 2016 Feb;23(1):e49-56. (PMID: 26966413)
Oncol Lett. 2017 May;13(5):3395-3402. (PMID: 28521445)

Keywords: HBV; HCC; Hepatitis B virus; epigenetic modification; hepatocellular carcinoma

Date Created: 20241026 Date Completed: 20241121 Latest Revision: 20241209

20241210

PMC11583590

10.1080/21505594.2024.2421231

39460469